WALTHAM, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:30 p.m. ET. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
About Proteon Therapeutics
Proteon Therapeutics Inc. is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass. For additional information, please visit www.proteontherapeutics.com.
About The BIO CEO & Investor Conference
The 17th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2014 CEO & Investor Conference featured 1,820 partnering meetings, 149 company presentations, and 1,400 attendees, over half of which were investors.
George Eldridge, Senior Vice President and Chief Financial Officer
Chris Erdman or Lynnea Olivarez, MacDougall Biomedical Communications
Proteon Therapeutics Inc.